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BACKGROUND
We hypothesized that mass distribution of a broad-spectrum antibiotic agent to pre-
school children would reduce mortality in areas of sub-Saharan Africa that are cur-
rently far from meeting the Sustainable Development Goals of the United Nations.
METHODS
In this cluster-randomized trial, we assigned communities in Malawi, Niger, and 
Tanzania to four twice-yearly mass distributions of either oral azithromycin (approxi-
mately 20 mg per kilogram of body weight) or placebo. Children 1 to 59 months of 
age were identified in twice-yearly censuses and were offered participation in the 
trial. Vital status was determined at subsequent censuses. The primary outcome was 
aggregate all-cause mortality; country-specific rates were assessed in prespecified 
subgroup analyses.
RESULTS
A total of 1533 communities underwent randomization, 190,238 children were identi-
fied in the census at baseline, and 323,302 person-years were monitored. The mean 
(±SD) azithromycin and placebo coverage over the four twice-yearly distributions was 
90.4±10.4%. The overall annual mortality rate was 14.6 deaths per 1000 person-years 
in communities that received azithromycin (9.1 in Malawi, 22.5 in Niger, and 5.4 in 
Tanzania) and 16.5 deaths per 1000 person-years in communities that received pla-
cebo (9.6 in Malawi, 27.5 in Niger, and 5.5 in Tanzania). Mortality was 13.5% lower 
overall (95% confidence interval [CI], 6.7 to 19.8) in communities that received 
azithromycin than in communities that received placebo (P<0.001); the rate was 5.7% 
lower in Malawi (95% CI, −9.7 to 18.9), 18.1% lower in Niger (95% CI, 10.0 to 25.5), 
and 3.4% lower in Tanzania (95% CI, −21.2 to 23.0). Children in the age group of 1 to 
5 months had the greatest effect from azithromycin (24.9% lower mortality than that 
with placebo; 95% CI, 10.6 to 37.0). Serious adverse events occurring within a week 
after administration of the trial drug or placebo were uncommon, and the rate did not 
differ significantly between the groups. Evaluation of selection for antibiotic resistance 
is ongoing.
CONCLUSIONS
Among postneonatal, preschool children in sub-Saharan Africa, childhood mortality 
was lower in communities randomly assigned to mass distribution of azithromycin 
than in those assigned to placebo, with the largest effect seen in Niger. Any imple-
mentation of a policy of mass distribution would need to strongly consider the poten-
tial effect of such a strategy on antibiotic resistance. (Funded by the Bill and Melinda 
Gates Foundation; MORDOR ClinicalTrials.gov number, NCT02047981.)
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Trachoma-control programs have distributed more than 600 million doses of oral azithromycin in an effort to elimi-
nate the ocular strains of chlamydia that cause 
the disease.1,2 Azithromycin has been effective 
against trachoma, although it has caused gastro-
intestinal side effects and selected for macrolide-
resistant strains of Streptococcus pneumoniae and 
Escherichia coli.3-8 Investigators have also noted 
possible benefits of azithromycin for prevention 
of a number of infectious diseases including 
malaria, infectious diarrhea, and pneumonia.9-14 
The results of a case–control study and a cluster-
randomized trial in an area of Ethiopia in which 
trachoma is endemic suggested that mass distri-
bution of azithromycin might reduce childhood 
mortality.15,16 Some experts believed that a mor-
tality benefit was, indeed, possible, although it 
would probably be smaller in magnitude than 
what was found in these studies.17
We tested the hypothesis that twice-yearly 
mass distributions of oral azithromycin would 
reduce mortality in children 1 to 59 months of 
age. The trial was performed in three geograph-
ically distinct areas: Malawi in southern Africa, 
Niger in West Africa, and Tanzania in East Africa. 
Azithromycin affects transmissible diseases, so 
the treatment of one person might have an effect 
on others in the same community. Thus, random-
ization and intervention were conducted at the 
community level, and inferences of efficacy were 
made at the community level. Since death is a 
relatively rare event even in these settings, a large 
trial population was required. Therefore, we ad-
opted a trial strategy with a straightforward in-
tervention and primary outcome.18
Me thods
Eligibility
MORDOR (Macrolides Oraux pour Réduire les 
Décès avec un Oeil sur la Résistance) was a 
cluster-randomized trial conducted in the Mala-
wian district of Mangochi, in the Nigerien dis-
tricts of Boboye and Loga, and in the Tanzanian 
districts of Kilosa and Gairo, with communities 
as the unit of randomization. The community 
that served as the randomization unit was a 
health surveillance assistance area in Malawi, a 
grappe (i.e., a cluster of households representing 
the smallest government health unit) in Niger, 
and a hamlet in Tanzania. None of the districts 
were eligible for mass distributions of azithro-
mycin for trachoma on the basis of the most 
recent mapping, and none of the children who 
participated in the trial had previously received 
azithromycin. Enrollment was based on census 
information available before the trial. Commu-
nities with a population between 200 and 2000 
inhabitants on the most recent census were eli-
gible for enrollment (see the Supplementary Ap-
pendix, available with the full text of this article 
at NEJM.org). Communities remained in the trial 
even if the population drifted out of this range. 
All children 1 to 59 months of age (truncated to 
month) who weighed at least 3800 g were eligi-
ble to receive azithromycin or placebo.
Randomization and Masking
Lists of communities from the most recent pre-
trial census were submitted to the data coordi-
nating center at the University of California, San 
Francisco (UCSF). For each country, communities 
were randomly assigned in equal proportions to 
1 of 10 letters, with 5 letters coded for azithro-
mycin and 5 for placebo (more information is 
provided in the statistical analysis plan in the 
protocol, available at NEJM.org). Randomization 
was performed with the sample function in R soft-
ware, version 3.1 (R Foundation for Statistical 
Computing). Only key trial personnel were aware 
of which letters corresponded to each group. 
Participants, observers, investigators, and data-
cleaning team members were unaware of the 
group assignments. Centralized randomization 
and simultaneous assignment of communities 
facilitated complete concealment of the assign-
ments. The placebo contained the vehicle of the 
oral azithromycin suspension and was bottled 
and labeled identically to azithromycin. Both 
placebo and azithromycin were donated by Pfizer, 
which reviewed the protocol but had no other 
role in the trial.
Census
A house-to-house census was performed during 
five prescribed 6-month periods, with allowance 
for a 2-month grace period for the initial census. 
At the initial census, all households in the com-
munity were recorded in a custom-built mobile 
application (Conexus); the name of the head of 
household and the global positioning system 
coordinates were used to facilitate location of the 
household for the following census. All children 
A Quick Take 
is available at 
NEJM.org
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1 to 59 months of age in the household were 
identified. Pregnant women and children young-
er than 1 month of age were also documented in 
anticipation of the next census. At follow-up cen-
suses, the vital status (alive, dead, or unknown) 
and residence (living in community, moved out-
side community, or unknown) were recorded for 
the children who had been present in the previ-
ous census records. Pregnant women and chil-
dren younger than 1 month of age were docu-
mented, and children 1 to 59 months of age who 
had moved into the community after the previous 
census were also documented and were offered 
participation. Census data were collected in com-
munities in the same general order throughout 
the trial. Data were uploaded to the Salesforce 
cloud database service (Salesforce). Data clean-
ing was performed with the use of the Salesforce 
platform; Stata software, version 13.1 (Statacorp); 
and R software.
Intervention
Each child 1 to 59 months of age at the time of 
the census was offered a single directly observed 
dose of oral azithromycin or placebo (according 
to the randomization of their community). Chil-
dren were given a volume of suspension corre-
sponding to at least 20 mg per kilogram of body 
weight, calculated with the use of a height stick 
(see the protocol), in accordance with the coun-
try’s trachoma program guidelines, or by weight 
for children unable to stand. Children who were 
known to be allergic to macrolides were not 
given azithromycin or placebo. Azithromycin or 
placebo was administered at the time of the 
census or during additional visits in an attempt 
to achieve at least 80% coverage. Administration 
of trial medication or placebo was documented 
in the mobile application for each child, and com-
munity coverage was calculated relative to the 
census. The parents or guardians of the children 
and the local health posts were instructed to 
contact a village representative regarding any 
adverse events noted within 7 days after admin-
istration of azithromycin or placebo; the village 
representative reported the events to the site coor-
dinator, who in turn reported the events to UCSF.
Primary Outcome
The prespecified primary outcome was the com-
munity-level, aggregate, three-country mortality 
rate determined with the use of data from twice-
yearly censuses. Each intercensal period was 
analyzed separately, with a death counted only 
when a child was recorded as having been alive 
and living in the household at the time of one 
census and recorded as having died while resid-
ing in the community by the time of the next 
census. By design, no attempt was made to track 
down a child’s status after the child moved out 
of the community. Person-time at risk was mea-
sured as the days between consecutive censuses; 
children who moved, died, or had an unknown 
follow-up status contributed to one half of the 
intercensal period. All children documented as 
being alive and residing in the household at the 
time of the initial census of each intercensal 
period were included in the analysis. No changes 
to trial outcomes were made after the trial had 
begun.
Subgroup Analyses
Mortality rates were assessed according to coun-
try site and age group. An abbreviated version of 
the 2007 World Health Organization (WHO) ver-
bal autopsy questionnaire for children 4 weeks 
to 14 years of age was used to collect data for 
verbal autopsies.19 Causes of death were assigned 
according to an algorithm based on a published 
verbal autopsy hierarchy.20
Trial Oversight
Approval for the trial was obtained from the 
ethics committees at the College of Medicine, 
University of Malawi, Blantyre; the Niger Minis-
try of Health; the Tanzanian National Institute for 
Medical Research; the London School of Hygiene 
and Tropical Medicine; the UCSF Committee on 
Human Research; Emory University; and Johns 
Hopkins University School of Medicine. Oral 
informed consent was obtained in Malawi and 
Niger, and written informed consent was ob-
tained in Tanzania. The trial was conducted in 
accordance with the principles of the Declaration 
of Helsinki. No incentives were offered for par-
ticipation. All children in the communities in 
Niger were offered treatment with azithromycin 
at the conclusion of the trial. By design, commu-
nities in Malawi were entered into the country’s 
trachoma-control program, even though prior 
district-level data had not met the criteria for 
mass distribution.
A data and safety monitoring committee pro-
vided oversight. The members of the steering 
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committee (see the Supplementary Appendix), 
who were also investigators in the trial, de-
signed the trial and vouch for the accuracy and 
completeness of the data and for the fidelity of 
the trial to the protocol. Full details of the trial 
design and analyses are provided in the protocol 
and the statistical analysis plan. The last author 
wrote the initial draft of the manuscript. All the 
authors contributed to subsequent revisions and 
agreed to submit the manuscript for publication.
Statistical Analysis
We estimated that the inclusion of 620 commu-
nities per country would provide at least 80% 
power to detect 10% lower all-cause mortality 
overall with azithromycin than with placebo. 
Specifically, we assumed that mortality rates 
would be between 14 and 20 deaths per 1000 
person-years in the placebo group, that the aver-
age community sizes would be 600 to 799 people 
(of whom 16.7 to 19.0% would be children 1 to 
59 months of age), that coefficients of variation 
would be between 0.40 and 0.51, and that the 
loss to follow-up would be 10%.
The prespecified primary analysis was nega-
tive binomial regression of the number of deaths 
per community, with treatment group and coun-
try as predictors and total person-time at risk as 
an offset. All three country sites contributed to 
the primary outcome. Hypothesis testing was 
two-sided, with an overall alpha level of 0.05 for 
the interim and final analyses. P values were de-
termined with Monte Carlo permutation testing 
(10,000 replications). An interim efficacy analy-
sis after the 12-month census was designed to 
spend 0.001 of the overall alpha level, with an 
alpha level of 0.049 reserved for the primary 
24-month analysis. Community-level clustering 
was taken into account by the dispersion param-
eter in the negative binomial regression model. 
Prespecified subgroup analyses included nega-
tive binomial regression of community-level mor-
tality rates according to country, age group, and 
intercensal period (details are provided in the 
statistical analysis plan in the protocol). A sample 
of 250 verbal autopsies were randomly selected 
from each country site and were compared with 
the use of the chi-square statistic, with cluster-
ing taken into account by community-level per-
mutation. All statistical analyses were conducted 
with R software.
R esult s
Participating Communities
A total of 1624 communities were eligible for 
inclusion in the trial on the basis of the most 
recent census (Fig. 1). A random selection of 1533 
communities were included in the current trial, 
and the remaining 91 were enrolled in smaller 
parallel trials at each site, in which additional 
microbiologic, anthropometric, and adverse-event 
data were collected. In Niger, 1 community de-
clined to participate and 20 were excluded be-
cause of census inaccuracies. No randomization 
units were lost to follow-up after the initial 
census.
Census periods started in December 2014, 
August 2015, February 2016, August 2016, and 
February 2017. At the baseline census, 97,047 
children were enrolled in the azithromycin group 
and 93,191 in the placebo group (Table 1). Over 
the five census visits, 323,302 person-years were 
monitored, including 111,559 person-years in 
Malawi, 145,597 person-years in Niger, and 66,146 
person-years in Tanzania. To validate data col-
lection, another census of a random subset of at 
least 200 households was conducted later during 
the same census period by an independent field 
team; most children who were counted in these 
later censuses had been counted in the earlier 
census: 95% (257 of 271) in Malawi, 92% (286 of 
Figure 1 (facing page). Enrollment, Randomization,  
and Treatment.
Communities in the three countries were enrolled and 
randomly assigned to distribution of azithromycin or 
placebo; censuses were carried out twice yearly for a 
total of five times over the course of the trial. Children 
1 to 59 months of age at the time of a census were eli­
gible to receive oral azithromycin or placebo, according 
to the randomization of their community. Enrollment 
criteria were identical for all three sites. Distribution  
by randomization unit is expressed as the estimated 
mean (±SD) for the population. Communities were 
 excluded before randomization primarily because they 
had a population on the most recent census of fewer 
than 200 or more than 2000 persons or because the 
communities were not required for the target sample 
size. Communities were excluded after randomization 
because of errors on the most recent census, including 
duplicate communities with different spellings, non­
existent communities, or satellite communities that 
had become indistinguishable from larger neighboring 
communities.
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310) in Niger, and 95% (4544 of 4791) in Tanza-
nia. Azithromycin was administered to a mean 
(±SD) of 90.3±10.6% of the targeted population, 
and placebo was administered to 90.4±10.1% 
(see the Supplementary Appendix). The main 
reason that a child did not receive azithromycin 
or placebo was that the child was away from the 
household at the time of the trial visit.
1624 Underwent randomization
334 Were in Malawi
646 Were in Niger
644 Were in Tanzania
2260 Communities in 3 countries were enrolled
516 Were in Malawi
732 Were in Niger
1012 Were in Tanzania
636 Were excluded
182 Were in Malawi
86 Were in Niger
368 Were in Tanzania
1533 Were enrolled in the current trial
and underwent randomization
91 Were enrolled in parallel trials
30 Were in Malawi
31 Were in Niger
30 Were in Tanzania
767 Were assigned to distribution of
azithromycin
152 Were in Malawi
(259±121 children per community)
308 Were in Niger
(133±93 children per community)
307 Were in Tanzania
(56±29 children per community)
766 Were assigned to distribution of placebo
152 Were in Malawi
(260±123 children per community)
307 Were in Niger
(123±88 children per community)
307 Were in Tanzania
(58±33 children per community)
5 In Niger were excluded
1 In Niger declined
to participate
15 In Niger were excluded
164,658 Person-yr were analyzed
55,273 Person-yr in Malawi
(364±167 per community)
76,873 Person-yr in Niger
(254±178 per community)
32,512 Person-yr in Tanzania
(106±55 per community)
158,644 Person-yr were analyzed
56,286 Person-yr in Malawi
(373±169 per community)
68,724 Person-yr in Niger
(236±167 per community)
33,634 Person-yr in Tanzania
(110±58 per community)
279,353 Doses were administered
109,159 Were administered in Malawi
(91±4% coverage) 
123,129 Were administered in Niger
(95±4% coverage)
47,065 Were administered in Tanzania
(87±11% coverage)
267,882 Doses were administered
109,937 Were administered in Malawi
(92±4% coverage) 
108,800 Were administered in Niger
(95±4% coverage)
49,145 Were administered in Tanzania
(88±4% coverage)
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Primary Results
The results of a 12-month interim analysis for 
efficacy did not meet the prespecified criterion 
for early stopping, which was a P value of less 
than 0.001 for the difference between groups. At 
the end of the trial, the annual mortality rate for 
eligible children in the three countries combined 
was 14.6 deaths per 1000 person-years in com-
munities that received azithromycin (9.1 per 
1000 person-years in Malawi, 22.5 in Niger, and 
5.4 in Tanzania) and 16.5 deaths per 1000 person-
years in communities that received placebo (9.6 
per 1000 person-years in Malawi, 27.5 in Niger, 
and 5.5 in Tanzania). Community-level, intention-
to-treat analysis showed that over all four inter-
censal periods, mortality was 13.5% lower over-
all (95% confidence interval [CI], 6.7 to 19.8) in 
the azithromycin group than in the placebo 
group (P<0.001). The proportion of children 
whose census status was recorded as moved or 
unknown did not differ significantly between 
the groups (P = 0.71 and P = 0.36, respectively).
Subgroup Results
Mortality rates were 5.7% lower (95% CI, −9.7 to 
18.9) in the azithromycin group than in the pla-
cebo group in Malawi (P = 0.45), 18.1% lower 
(95% CI, 10.0 to 25.5) in Niger (P<0.001), and 
3.4% lower (95% CI, −21.2 to 23.0) in Tanzania 
(P = 0.77) (Fig. 2). Children in the youngest age 
group (1 to 5 months of age) had the highest 
overall mortality and the largest observed differ-
ence in mortality with azithromycin as compared 
with placebo (24.9% lower with azithromycin; 
95% CI, 10.6 to 37.0; P = 0.001) (Fig. 3). In the 
first period, mortality was 17.3 per 1000 person-
years in the communities assigned to placebo 
and 16.1 per 1000 person-years in the communi-
ties assigned to azithromycin (an estimated 7.3% 
lower mortality with azithromycin; 95% CI, −5.9 
to 18.8; P = 0.26). In the last period, mortality 
was 16.1 per 1000 person-years in the communi-
ties assigned to placebo and 13.1 per 1000 person-
years in the communities assigned to azithromy-
Characteristic All Countries Malawi Niger Tanzania
Azithromycin Placebo Azithromycin Placebo Azithromycin Placebo Azithromycin Placebo
No. of communities 762 750 152 152 303 291 307 307
No. of children 97,047 93,191 39,386 39,534 40,345 35,747 17,316 17,910
No. of children per 
community
171±126 169±128 259±121 260±123 133±93 123±88 56±29 58±33
Male sex (%) 50.7 50.6 50.2 50.0 51.2 51.4 50.5 50.6
Age group (%)
1–5 mo 7.4 7.4 7.0 6.9 6.8 6.9 9.4 9.2
6–11 mo 13.2 13.2 12.3 12.3 13.5 13.6 14.5 14.5
12–23 mo 19.1 19.2 20.5 20.2 17.0 16.8 21.0 21.8
24–59 mo 60.4 60.2 60.2 60.6 62.8 62.7 55.1 54.5
*  Plus–minus values are means ±SD. Percentages may not total 100 because of rounding.
Table 1. Baseline Characteristics of the Communities and Participants in the Azithromycin and Placebo Groups.*
Figure 2. Efficacy of Azithromycin Overall and by Country.
Shown is the estimated percent lower mortality with 
twice­yearly distributions of oral azithromycin than 
with placebo. I bars indicate 95% confidence intervals.
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cin (22.0% lower mortality; 95% CI, 10.6 to 31.9; 
P<0.001) (Fig. 4). Efficacy did not differ sig-
nificantly between the two groups by country 
(P = 0.17), age group (P = 0.20), treatment period 
(P = 0.09), or treatment coverage (P = 0.34).
 Causes of Death
In a random sample of 250 verbal autopsies from 
each of the three sites, we estimated that 41% of 
the deaths were due to malaria, 18% to diarrhea 
or dysentery, and 12% to pneumonia (see the 
Figure 3. Efficacy of Azithromycin by Age Group.
Shown is the estimated percent lower mortality with twice­yearly distributions of oral azithromycin than with placebo, 
according to age group at the time of treatment. Younger children had the greatest benefit in all three countries. I bars 
indicate 95% confidence intervals.
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Figure 4. Efficacy of Azithromycin over Time.
Shown is the estimated percent lower mortality with twice­yearly distributions of oral azithromycin than with placebo 
over each of the four 6­month time periods. The aggregate efficacy of azithromycin as compared with placebo in­
creased in each progressive time period. I bars indicate 95% confidence intervals.
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Supplementary Appendix). Causes of death dif-
fered significantly among the countries (P<0.001), 
with relatively more deaths attributed to malaria 
in Niger and more to pneumonia in Tanzania.
Adverse Events
Trial personnel were notified of 20 hospitaliza-
tions and life-threatening illnesses (see the Sup-
plementary Appendix). Medical review was un-
able to determine whether any serious adverse 
event was caused by azithromycin. Nonserious 
adverse events were difficult to detect in the 
context of this trial, and they were reported less 
frequently than serious adverse events. No assess-
ment of antimicrobial resistance was made in 
the communities that participated in the trial.
Discussion
In a trial involving postneonatal, preschool chil-
dren in sub-Saharan Africa, all-cause mortality 
was significantly lower, by approximately 14%, 
among children who received a twice-yearly dose 
of oral azithromycin than among children who 
received placebo. The highest number of deaths 
and the largest observed effect was seen in Niger, 
in which mortality was 18% lower with azithro-
mycin than with placebo. In subgroup analyses, 
significantly lower mortality with azithromycin 
than with placebo was observed only in Niger. 
The overall 14% effect was less than that seen 
in a previous case–control study and in a cluster-
randomized trial in Ethiopia, but it was in line with 
the 18% effect that a group of experts had an-
ticipated in a poll conducted before this trial.15-17
Azithromycin was most effective among chil-
dren 1 to 5 months of age, preventing 1 of 4 deaths 
expected among children in this age group. The 
Food and Drug Administration has not approved 
azithromycin for children in this age group, and 
the WHO does not currently recommend includ-
ing them in distributions to control trachoma.21 
However, the Centers for Disease Control and 
Prevention does recommend oral azithromycin 
for all ages for the treatment and prophylaxis of 
pertussis.22 Any plan for mass distribution to 
children 1 month of age or younger would need 
to consider the risk of inducing infantile hyper-
trophic pyloric stenosis.23-25
This trial did not investigate the mechanism 
by which azithromycin reduced mortality. Before 
the trial, experts thought that a protective effect 
would most likely be due to reductions in respi-
ratory infections, diarrhea, and malaria (in that 
order).17 Such a hypothesis seems reasonable, 
given the activity of azithromycin against bacte-
rial pathogens of the lungs and gastrointestinal 
tract and against the Plasmodium falciparum apico-
plast. Further study will be necessary to identify 
the mechanism by which azithromycin prevents 
death. Investigation is already under way. Smaller 
parallel trials at each trial site collected addi-
tional data from detailed microbiologic, anthro-
pometric, and adverse-event assessments. Infer-
ences from these smaller trials will be directly 
applicable to the mortality result because the 
communities were chosen at random from the 
same pool as the parent trial. Azithromycin has 
been linked to death from cardiac causes in 
adults, although results of studies are mixed and 
may not be relevant to children in sub-Saharan 
Africa.26-30 In this community-based trial, and 
even the more detailed parallel studies, QT inter-
vals could not be monitored, as would be possible 
in a hospital-based setting.28
Nonspecific use of antibiotics is discouraged 
because of concern about antibiotic resistance. 
Repeated mass distributions of azithromycin 
for trachoma control select for macrolide resis-
tance in nasopharyngeal S. pneumoniae and rectal 
E. coli.6-8,31,32 Resistance emerging during mass 
azithromycin distributions could curb or even 
reverse any potential benefit with respect to 
mortality. We did not observe such a waning ef-
fect on mortality in this trial — in fact, the ob-
served effect increased from 7% to 22% over the 
four twice-yearly intercensal periods. Nonethe-
less, longer follow-up is warranted to determine 
whether the mortality effect observed in the 
current trial changes with subsequent rounds of 
treatment.
The trial had several limitations. First, given 
the design, little information was collected on 
each individual child and community. Second, 
deaths were determined by consecutive censuses. 
Children who were born after one census and 
died before the next census did not contribute to 
either the number of deaths or the person-time at 
risk for the primary outcome. Secondary analy-
ses may reveal whether these children benefited 
from living in a community treated with azithro-
mycin even if they were not born in time to be 
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included in community treatment. Third, no effort 
was made to follow children after they moved. 
Death rates may have differed among children 
who moved or had an unknown census status. 
Fourth, with twice-yearly distributions, a child’s 
first treatment might not have been adminis-
tered until 7 months of age. Supplementary treat-
ments given to infants during a scheduled vac-
cination visit to a health clinic could potentially 
add benefit. Fifth, although mortality is seasonal, 
for logistic reasons communities were treated in 
a rolling fashion over each 6-month period. Sec-
ondary analyses may reveal whether the drug 
was particularly effective in certain seasons. 
Finally, although the trial was performed in 
three geographically diverse sites, the results 
may not be generalizable outside these districts. 
Subgroup analyses confirmed a significantly low-
er rate with azithromycin than with placebo in 
only one of the three sites.
Across three sites in sub-Saharan Africa, child-
hood mortality was significantly lower among 
children who received two doses of oral azithro-
mycin per year than among those who received 
placebo. The largest effect was found in Niger, 
which has one of the highest child mortality 
rates in the world. Further investigation is re-
quired to identify specific mechanisms by which 
azithromycin reduced mortality. Any policy that 
recommends mass distribution of oral azithro-
mycin to address childhood mortality would 
need to consider not only cost but also the risk 
of side effects, especially the potential for the 
induction or amplification of antibiotic resis-
tance.33
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